
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is a biotech company that is primarily focused on the development of Ampligen, a dsRNA molecule, for the treatment of various types of cancer, including late-stage pancreatic cancer. The company has a positive outlook, with upcoming catalysts expected from clinical data and a focus on a high-reward market. Additionally, the company has a strong balance sheet with enough cash into late-2026 and a current valuation that reflects its potential for high growth and upside opportunities. While there are risks associated with the long development road of its oncology drugs, the potential billion-dollar market presents a high reward for investors.
Bears say
AIM ImmunoTech is currently facing financial challenges as reflected by its weak balance sheet and repeated fundraising activities. Moreover, its recent Q4 results showed a higher-than-expected net loss, which could impact investor confidence. However, with a promising pipeline focused on important areas of unmet medical needs and a current attractive valuation, the company may still have potential for growth in the long term.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares